Search Results - "Szapary, P.O."

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up by Langley, R.G., Lebwohl, M., Krueger, G.G., Szapary, P.O., Wasfi, Y., Chan, D., Hsu, M.C., You, Y., Poulin, Y., Korman, N., Prinz, J.C., Reich, K.

“…Summary Background Evaluation of the dosing flexibility and long‐term efficacy of biological agents is limited. Objectives To evaluate the long‐term efficacy…”
Get full text

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up by Papp, K.A., Griffiths, C.E.M., Gordon, K., Lebwohl, M., Szapary, P.O., Wasfi, Y., Chan, D., Hsu, M.-C., Ho, V., Ghislain, P.D., Strober, B., Reich, K.

“…Summary Background  Long‐term safety evaluations of biologics are needed to inform patient management decisions. Objectives  To evaluate the safety of…”
Get full text

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years by Kimball, A.B., Gordon, K.B., Fakharzadeh, S., Yeilding, N., Szapary, P.O., Schenkel, B., Guzzo, C., Li, S., Papp, K.A.

“…Summary Background  An unmet need remains for safe and effective long‐term treatments of psoriasis. Objectives  To evaluate ustekinumab efficacy and safety for…”
Get full text

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up: Long-term ustekinumab safety in psoriasis by Papp, K.A., Griffiths, C.E.M., Gordon, K., Lebwohl, M., Szapary, P.O., Wasfi, Y., Chan, D., Hsu, M.-C., Ho, V., Ghislain, P.D., Strober, B., Reich, K.

Get full text

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years: Long-term efficacy of ustekinumab in moderate-to-severe psoriasis by Kimball, A.B., Gordon, K.B., Fakharzadeh, S., Yeilding, N., Szapary, P.O., Schenkel, B., Guzzo, C., Li, S., Papp, K.A.

Get full text

Cancers survenus dans le programme de développement clinique sur le traitement du psoriasis par l’ustekinumab : rapport final portant sur un suivi de cinq ans by Papp, K.-A., Gordon, K.-B., Ho, V., Szapary, P.O.

Get full text

Tolérance cardiovasculaire évaluée dans le cadre du programme de développement clinique portant sur le traitement du psoriasis par l’ustekinumab : rapport final portant sur un suivi de cinq ans by Reich, K., Lebwohl, M., Griffiths, C.E., Szapary, P.O.

Get full text

Le traitement à long terme par l’ustekinumab ne compromet pas la réponse immunitaire à des vaccins T dépendant ou T indépendant chez les patients avec un psoriasis modéré à sévère : comparaison de patients psoriasiques traités par l’ustekinumab versus des témoins by Brodmerkel, C., Langley, R.G., Papp, K.A., Bourcier, M., Poulin, Y., Ho, V., Guenther, L.C., Hsu, M.-C., Szapary, P.O.

Get full text

Efficacité et sécurité à long terme de l’ustekinumab chez les patients atteints de psoriasis modéré à sévère après cinq ans de suivi : résultats de l’extension à long terme de PHOENIX 1 by Kimball, A.B., Papp, K.A., Wasfi, Y., Chan, D., Bissonnette, R., Sofen, H.L., Yeilding, N., Li, S., Szapary, P.O., Gordon, K.B.

Get full text

Tolérance à long terme de l’ustekinumab chez les patients atteints de psoriasis modéré à sévère jusqu’à cinq ans de suivi continu by Papp, K.A., Griffiths, C.E., Gordon, K.B., Lebwohl, M., Szapary, P.O., Wasfi, Y., Chan, D., Hsu, M.-C., Ho, V., Ghislain, P.-D., Strober, B., Reich, K.

Get full text

Th-P16:322 Microsomial transfer protein (MTP) inhibition substantially reduces cholesterol in patients with homozygous familial hypercholesterolemia by Cuchel, M., Bloedon, L.T., Kolansky, D.M., Szapary, P.O., Wolfe, M.L., Millar, J.S., Ikewaki, K., Siegelman, E.S., Gregg, R.E., Rader, D.J.

Get full text

Guggulipid for the treatment of hypercholesterolemia. A randomized controlled trial by Szapary, P.O., Wolfe, M.L., Bloedon, L.T.

Get full text